Chapter 9 The Value of Mammalian Models for Duchenne Muscular Dystrophy in Developing Therapeutic Strategies
Authors:
- Jeffrey S. ChamberlainJCJeffrey S. Chamberlain
- 1 January 2008
- book chapter
- Published by Elsevier
- Vol. 84, 431-453
Abstract
No abstract availableKeywords
This publication has 143 references indexed in Scilit:
- Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient MiceMolecular Therapy, 2008
- Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic DogsMolecular Therapy, 2008
- Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiencyProceedings of the National Academy of Sciences, 2008
- Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophyNature Medicine, 2008
- Skeletal muscle satellite cells and adult myogenesisCurrent Opinion in Cell Biology, 2007
- Asymmetric Self-Renewal and Commitment of Satellite Stem Cells in MuscleCell, 2007
- Mechanosensitive channel properties and membrane mechanics in mouse dystrophic myotubesThe Journal of Physiology, 2007
- PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophyGenes & Development, 2007
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003